Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer

Current Oncology

Volumn 19, Issue 4, 2012, Pages

  Golfam, M ^a   Samant, R ^a   Eapen, L ^a   Malone, S ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Anemia; Prostate cancer; Radiotherapy; Total androgen blockade

Indexed keywords

BICALUTAMIDE; ERYTHROPOIETIN; GOSERELIN; HEMOGLOBIN; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MALE; MONOTHERAPY; PROSPECTIVE STUDY; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84865182882     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.963     Document Type: Article

References (22)

1. Boccon-Gibod L, Richaud P, Coloby P, et al. First-line indications for hormonal therapy in prostate cancer [French]. Prog Urol 2010;20:109-15.
2. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 2010;8:211-23.
3. Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010;85:110-20.
4. Bolla M, de Reijke TM, Van Tienhoven G, et al. on behalf of the eortc Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
5. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
6. Hamilton JB. The role of testicular secretions as indicated by the effects of castration in man and by studies of pathological conditions and the short life span associated with maleness. Recent Prog Horm Res 1948;3:257-322.
7. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007;9(suppl 1):S3-8.
8. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66(suppl 5):1039-44.
9. Eisenberger M, Crawford ED, McLeod D, Loehrer P, Wilding G, Blumenstein B. A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (pc) (nci INT-0105 swog/ecog) (Meeting abstract) [abstract 3]. J Clin Oncol 1997;15:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=30&abstractID=3928; cited June 20, 2012]
10. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (lhrh agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985;23:833-41.
11. Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int 2009;83:373-8.
12. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
13. Curtis KK, Adam TJ, Chen SC, Pruthi RK, Gornet MK. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008;11:157-61.
14. Beer TM, Tangen CM, Bland LB, et al. on behalf of Southwest Oncology Group Study. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006;107:489-96.
15. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in the treatment of benign prostatic hyperplasia. J Urol 1994;152:448-52.
16. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-41.
17. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996;29:243-8.
18. Boustany R, Zerbib M. Anaemia and prostatic cancer [French]. Prog Urol 2005;15:604-10.
19. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991;36:190-4.
20. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-72.
21. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of getug-01. J Clin Oncol 2007;25:5366-73.
22. Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999;83:43-6.